Advanced Accelerator Applications Reports over 24% Growth in Sales for the First Quarter of 2015
Advanced Accelerator Applications S.A. ("AAA" or "The Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced its financial results for the first quarter of 2015.
AAA Fully Acquires Atreus Pharmaceuticals; Enrolls First Patient in a Phase I/II Clinical Trial for Its Key Diagnostic Candidate Annexin v-128 in Rheumatoid Arthritis
Advanced Accelerator Applications S.A. ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), announced that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada and focused on the development of proprietary molecular imaging products aimed at imaging apoptosis and necrosis based on Annexin V. Atreus Pharmaceuticals Corporation is now a fully owned AAA subsidiary and has been renamed AAA Canada.
AAA Acquires GE Healthcare's FDG-PET Radiopharmaceutical Business in Italy
Advanced Accelerator Applications (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM) announced today that it has entered into an agreement with GE Healthcare Italy to acquire their FDG-PET business (fluorodeoxyglucose photon emission tomography). This acquisition includes the SteriPET® (FDG) Marketing Licence. With this acquisition AAA reinforces its position as one of the leading companies in the PET market in Italy.
AAA Reports Full-Year 2013 Financial Results: Company Reports over 30% Growth in Sales
Advanced Accelerator Applications S.A. (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), is pleased to announce its results for the financial year 2013, with sales of €53.8 million (+31.77% vs. 2012).